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Objectives. To describe the pattem of prescribing for
hypertension at a community health centre (CHC) and to
evaluate the impact of introducing treatment guidelines
and restricting availability of less cost-effective
antihypertensive drugs on prescribing patterns, costs of
drug treatment and blood pressure (BP) control.
Design. Before/after intervention study.
Setting. Medium-sized CHC in the Cape Flats area of
Cape Town.
Subjects. 1 084 hypertensive patients attending the CHC,
who had at least two prescriptions for antihypertensive
drugs during a 1-year period starting on 1 January 1992.
Interventions. 1. Implementation of stepped-care
guidelines for hypertension, specifying treatment with
more cost-effective drugs and minimising drug treatment.
2. Reducing availability for routine prescribing by CHC
doctors of 10 less cost-effective antihypertensive drugs or
drug combinations.
Outcome measures. 1. Mean number of drugs
prescribed per patient. 2. Proportion of prescriptions for:
each major class of antihypertensive drug; restricted
availability and freely prescribable drugs; and more and
less cost-effective drugs. 3. Mean monthly cost of drugs
prescribed per patient. 4. Mean blood pressure and
proportion of BP readings controlled « 160/95 mmHg) or
uncontrolled (;;> 160/95 mmHg).
Results. A mean of 1.7 active drugs was prescribed per
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patient per visit. The most frequently prescribed drugs
were thiazide-like diuretics (44.8%), centrally acting agents
(28.4%) and b-blockers (13.2%). Mean monthly drug costs
per patient decreased significantly by R1.99 (24.2%) from
R8.24 to R6.25 between the first and last prescription for
each patient (exclusive of any reduction due to withdrawal
of treatment). This was attributable to reduced prescribing
of more expensive drugs withdrawn from routine use and
a 51.1 % increase in prescribing of the most cost-effective
drugs. The overall annual cost-saving of the changes in
prescribing for this CHC are estimated at R75 150. Blood
pressure control did not change significantly.
Conclusion. The pattern of changes in prescribing and
drug costs was consistent with a causal effect of the
interventions. The study demonstrates the potential for
improving cost-effectiveness of hypertension care in
primary care in South Africa and the potential for research
in this setting.
s AIr Med J 1998; 88: 549-554.
The National Health Plan for South Africa announced that
'the primary health care approach is the underlying
philosophy for the lestructuring of the health system' and
stressed the importance of the rational and appropriate use
of resources. One mechanism suggested for addressing the
growing problem of non-communicable disease in South
Africa was to develop programmes for the cost-effective
management of chronic diseases - for example. by
promoting cost-effective therapy through peer and utilisation
reviews, therapeutic guidelines and clinical audit.'
Hypertension is a major public health problem in South
Africa, Community-based surveys have found age-adjusted
prevalences of hypertension of 15 - 34%. Hypertension is
common throughout South Africa and in all ethnic groups
except perhap.., blacks with traditional lifestyles in deep rural
areas.2•3
Most patients with hypertension are treated in primary
care settings. There are clear international'" and South
African' consensus gUidelines describing best practice for
the care of hypertensive patients. New guidelines from the
Hypertension Society of Southern Africa for the
management of hypertension in primary care have been
published recently.'
These guidelines commonly encourage the use of well-
established drugs like thiazide diuretics, reserpine and b-
blockers as first-line treatment. There is more evidence from
randomised trials of the efficacy of these drugs in reducing
the occurrence of, and mortality from, stroke and heart
disease, '.9 compared with newer drugs like ACE inhibitors
and calcium antagonists.
An estimated 60 - 90% of the treatment costs of
hypertension are attributable to drugs." Prices of
antihypertensive drugs vary widely." For example, in 1992
the costs to Cape Province day hospitals of
hydrochlorothiazide and reserpine at typical doses were 12
and 6 cents per patient per month, respectively. ACE
inhibitors and newer b-blockers cost up to R30 per patient
per month, i.e. they are 250 - 500 times more expensive. A
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more recent comparison of tender, cost and dispensed retail
prices confirms that these differentials persist in South
Africa."
Therefore, it is widely agreed that treatment with cheaper,
well-established drugs is much more cost-effective.'"
Indeed, one proposal to increase the cost-effectiveness of
hypertension treatment in South Africa argued for mass
treatment using the cheapest drugs through low-cost outlets
such as community health centres (CHCs), formerly called
day hospitals.'3
This background, together with the present context of
severely limited resources for health care in South Africa,
underlines the importance of research into interventions to
improve the cost-effectiveness of prescribing. However,
there has been relatively little such research worldwide, and
almost none in South Africa. The only South African
reference we found was an analysis of cost-savings and
changes in blood pressure (BP) control following a change
from nifedipine to other drugs in 30 hypertensive patients."
We present a large prospective study of over 1 000
hypertensive patients from a Cape Town CHC. The aims
were to describe the pattern of prescribing for hypertension
and evaluate the impact of introducing treatment guidelines
and reducing the availability of more expensive
antihypertensives on: prescribing patterns, costs of drug
treatment and BP control.
Methods
Subjects and setting
The setting, subjects, sampling technique and methods of
data collection have been fully described in a previous
paper." Briefly, this was a before/after intervention study
performed at Or Abdurahman CHC in Athlone in the Cape
Flats area of Cape Town. This is a medium-sized CHC, with
a usual complement of four doctors, serving a largely
coloured population.
The subjects were 1 098 of 3 147 hypertension patients
attending the CHC during 1992. Fourteen of these patients
who had collected fewer than two prescriptions during the
study period were excluded from subsequent analysis.
Data collection
Hypertensive patients at this CHC were usually seen by
clinic staff every 2 months, by a doctor once every 4 months
(unless more frequent monitoring was clinically indicated,
the patient asked for an appointment sooner or was referred
by the primary care nurse), and by the primary care nurse in
the interim. Changes in treatment occurred only during
consultations with the doctor. Patients were given 4 weeks'
supply of antihypertensive drugs at each visit, and collected
repeat prescriptions between visits.
Drugs were dispensed from the hospital pharmacy.
Hypertensive drugs prescribed were recorded by the second
author (either during the consultation or retrospectively from
pharmacy records) for the first 12 due (Le. 4-weekly)
prescriptions of selected patients starting from January
1992. Prescriptions were not always collected at exact 4-
week intervals, and for a few patients the follow-up period
extended into early 1993. Some patients were newly
diagnosed as hypertensive during 1992. For these patients,
data were collected on the number of due prescriptions left
after subtraction of those that would have been written in
the period prior to diagnosis. (For example, for a patient
diagnosed in April, data were collected on their initial visit
and the next 8 due prescriptions.)
The information used for analysis was as follows: (I) first
and last recorded BP for each patient during the study
period; (if) name and dose of each antihypertensive drug
from the first and last prescription collected by each patient
during the study period; and (iif) total cost (in rand per
month) of antihypertensive drugs for each prescription and
for the first and last prescription collected by each patient
during the study period.
BP was measured either by the primary care nurse or
doctor. Costs of individual drugs were calculated by the
CHC pharmacy and represented the mean costs of the
drugs to the pharmacy in 1992.
Interventions
Treatment guidelines. In 1990, the Consultants' Committee
at Groote Schuur Hospital (GSH) issued guidelines for the
drug treatment of hypertension. These suggested a
stepped-care approach in which the aim was to control BP
with the least expensive treatments and the minimum
number of drugs. The guidelines advised clinicians to try to
reduce treatment (or withdraw it completely) in well-
controlled patients. The recommended steps for responding
to raised or poorly controlled BP were: (f) use a first-choice
drug (amiloride co, hydrochlorothiazide, propranolol or
reserpine); (if) combine two first-choice drugs; (iif) add a
vasodilator (hydralazine or verapamil); and (iv) add enalaprii
or captopril (in addition to the other drugs or in place of the
vasodilator). Steps (I) - (iif) drugs were much cheaper than
those in step (iv).
The guidelines were circulated to all CHCs in the Cape
Town area early in 1991. In the middle of 1991, the second
author issued doctors at Or Abdurahman CHC with copies
and asked them to implement the guidelines. The doctors
agreed to change, whenever possible, to more cost-effective
drugs when a change in medication was indicated as a
result of poor control, patient preference or side-effects.
Later in 1992, as confidence in the regimen increased, some
patients with well-controlled BP and no other indications to
alter therapy were changed to more cost-effective drugs. In
all cases, treatment decisions were taken by the attending
doctor, and treatment changed only where thought to be
clinically justifiable.
Restrictions on drug availability. At various times during
1992, the local drugs committee withdrew ten relatively
expensive antihypertensive drugs from routine use at the
CHC. The drugs that were withdrawn were: (f) b-blockers
(sotalol, metoprolol and nadolol); (if) diuretic or diuretic
combinations (indapamide, aldazide, chlortalidone and
cyclopentathiazide/potassium chloride); (iif) centrally acting
drugs, alone or in combination - c1onidine,
dehydroergocristine/c1opamide/reserpine; and (iv) a calcium
antagonist (diltiazem).
Analysis
Drugs were categorised in three different ways for analysis.
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1. To describe prescribing patterns, individual drugs were
assigned to eight different classes largely on the basis of the
classification in the South African Medicines Formulary'·
(Table I).
2. Antihypertensive drugs were also categorised
according to their availability to the CHC doctors: (I) 'CHC'
drugs were freely prescribable by CHC doctors throughout
the study period; (iJ) 'consultant' drugs were three expensive
antihypertensives (the ACE inhibitors, enalapril and captopril,
and the calcium antagonist, nifedipine), which had been
withdrawn from routine use by the local drug committee
before the study began. Treatment with these drugs could
only be initiated by consultants at secondary or tertiary
levels of care. CHC doctors could continue to prescribe
these drugs for patients transferred to their care for follow-
up, and were free to change the dose or withdraw the
treatment; and (iiJ) 'new consultant' drugs were ten
antihypertensives (see above) withdrawn from routine use
during the study period (prescriptions for these drugs were
dispensed until supplies were exhausted and then other
stepped-care drugs were substituted by the pharmacy after
consultation with the doctor), and which became subject to
the same prescribing restrictions as 'consultant' drugs.
Table I. Antihypertensive drug classes
1. ACE inhibitors, e.g. enalapril, captopril
2. b-blockers, e.g. propranolol, atenolol, metoprolol
3. Calcium antagonists, e.g. verapamil, nifedipine, diltiazem
4. Thiazide and thiazide-like diuretics, e.g. hydrochlorothiazide,
hydroflumethazide, indapamide, cyclopenthiazide
5. Centrally acting drugs, e.g. reserpine, methyldopa
6. Vasodilators, e.g. hydralazine
7. a-blockers, e.g. prazosin
8. Other diuretics, e.g. spironolactone
The examples given are the drugs that were commonly prescribed during the study.
3. Finally, drugs from steps (I) to (iil) in the GSH guidelines
were designated as cost-effective, compared with other
drugs in step (iv) or others not included in the stepped-care
protocol.
The mean number of drugs prescribed per visit and the
proportions of different drug classes prescribed were
determined by aggregating the prescriptions at the first and
last visit for each patient during the study.
All costs were calculated as mean monthly cost of
antihypertensive drugs per patient. Mean costs and the
relative contribution of 'CHC', 'consultant' and 'new
consultant' drugs were calculated for all patients collecting
drugs at each of the 12 due prescriptions. The denominator
was the number of patients collecting antihypertensive
drugs at each due prescription. Patients on no hypertensive
medication were excluded so that changes were
independent of the withdrawal of treatment. Mean drug
costs were also calculated for each patient's first and last
prescription during the study period.
BP control was analysed by comparison of mean BP and
proportion of patients controlled « 160/95 mmHg) and
uncontrolled (;;> 160/95 mmHg) from all patients' first and
last BP measurements during the study period. Seventy-two
patients who had had fewer than two BP measurements
during the year were excluded.
Statistical analysis was performed using Epi-Info 6.0
database and statistical analysis software. The chi-squared
test with Yates continuity correction was used to compare
proportions. Paired t-tests were used to test for significant
differences in the means of paired data.
Results
Prescribing patterns
A mean of 1.70 antihypertensive drugs was prescribed per
visit (1.62 if patients on no treatment were included). Most
prescriptions were for 1 (43.7%) or 2 (45%) drugs; 10.3%
were for 3 drugs and 1% for 4 drugs. (For these analyses,
each active antihypertensive agent within combination drugs
has been counted as a separate drug.) There was no
significant difference between the mean number of drugs
prescribed per patient at the first (1.71) and last (1.70)
prescription or in the proportions of patients on 1, 2, 3 or 4
drugs. There was a significant decrease from 1.67 to 1.57
drugs per patient between the first and last prescription if
patients on no treatment were included (mean difference
0.10,95% confidence interval 0.04 - 0.16 drugs per patient).
This was due to an increase in the number of patients on no
treatment between the first (6 patients, 0.6% of the total)
and last prescription (77 patients, 7.1 %).
Table 11. Proportion of drug classes prescribed
First and last prescription First prescription Last prescription
No. of No. of No. of
Class of antihypertensive treatment prescriptions % prescriptions % prescriptions %
ACE inhibitors 198 5.6 95 5.3 103 6.0
b-blockers 465 13.2 251 13.9 214 12.5
Calcium antagonists 169 4,8 81 4.5 88 5.2
Thiazide and thiazide-like diuretics 1 571 44.8 831 46.0 740 43.4
Centrally acting drugs 997 28.4 492 27.2 505 29.6
Vasodilators 70 2.0 22 1.2 48 2.8"
Other diuretics 29 0.8 12 0.7 2 0.1"
a-blockers 14 0.4 22 1.2 7 0.4'--
Total 3513 100.0 1 806 100.0 1 707 100.0
" Slgnrficam differences in proportions prescribed between first and last prescriptions le' test, P < 0.05).
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Patients on no hypertensive treatment or defautting at each visIT have been exduded.
Numbers coflecting prescriptions per visit are on the all drug costs line.
Mean cost of drugs (rand/patient/month)
10r----------------------,
Drug costs
The mean cost per patient at each due prescription is shown
in Fig. 1, together with the contribution from 'CHC',
'consultant' and 'new consultant' drugs. The figures exclude
patients who failed to collect medication at each visit, and
also those who had been taken off hypertensive treatment.
(The number of hypertensive patients on no treatment
increased steadily from 6 at the first visit to 63 at the
twelfth.)
Last visit
No. %
First visit
No. %
To explore the causes of this fall in drug costs further,
prescribing patterns and costs of drugs were analysed at
the first and last visit of 1 002 patients who were prescribed
antihypertensive treatment at both visits. This revealed a
statistically significant (P < 0.001) R1.99 (24.2%) decrease in
mean costs per patient of all antihypertensive drugs
prescribed, from R8.24 to R6.25 per patient per month. This
was due to significant (P < 0.001) decreases in the mean
costs per patient of R1.11 (76.0%) for 'new consultant' and
RO.98 (22.8%) for 'CHC' drugs. The cost attributable to
'consultant' drugs increased non-significantly.
The reduction in costs attributable to 'new consultant'
drugs was due to a reduced number of prescriptions from
296 to 107 between the first and last visits and a 43.8%
reduction in the mean monthly cost of individual drugs
prescribed from R4.95 to R2.78 per patient per month. The
reduction in costs associated with 'CHC' drugs was due to
a 32.8% fall in the mean cost of the individual drugs
prescribed from R3.28 to R2.22 per patient per month, and
occurred in spite of an increase in the number of
prescriptions of these drugs from 1 314 to 1 480 between
the first and last visits. The total number of prescriptions did
not change significantly, though the mean cost per drug
prescribed fell from R4.83 to R3.63 per patient per month.
The number of prescriptions and mean costs per
prescription of 'consultant' drugs did not change
significantly.
The cause of the fall in the mean cost of individual 'CHC'
drugs prescribed is shown in Table Ill. There was a
significant increase in the prescribing of most of the more
cost-effective drugs between the first and last visits. The
proportion of all prescriptions for drugs from steps (I) to (iil)
of the GSH guidelines increased by 51.1 % from 40.3% to
60.9% of the total.
Table Ill. Prescribing of more and less cost-effective drugs at first
and last prescription
'Step (I) drugs'
Hydrochlorothiazide/ 478 26.5 584 34.2"
moduretict
Propranolol 13 0.7 24 1.4
Reserpinet 158 8.7 309 18.1 "-- -- -- --
Total 649 35.9 917 53.7*
'Step (iil) drugs'
Verapamil 57 3.2 74 4.3
Hydralazine 22 1.2 48 2.8"-- -- -- --
Total 79 4.4 122 7.1 "
All drugs
Step (I) and (iil) drugs 728 40.3 1039 60.9"
Other drugs 1078 59.7 668 39.1"
-- --
Total active drugs prescribed 1806 1 707
1412108
Visit
6
1:) 'New consultanf drugs
• 'CHC' drugs
779 770 754 782
1000_ffiL _
884 821 861 799 811 797
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The proportion of prescriptions for each of the main
antihypertensive drug classes is shown in Table 11. The
commonest were thiazide and thiazide-like diuretics (44.8%),
centrally acting drugs (28.4%) and b-blockers (13.2%).
For patients on monotherapy the distribution was similar.
The commonest agents were thiazide and thiazide-like
diuretics (55.4%), followed by centrally acting drugs (17.8%),
b-blockers (11.5%), ACE inhibitors (10.9%) and calcium
antagonists (3.5%). Other drugs accounted for less than 1%
of monotherapy prescriptions.
For patients on two different drugs nearly all (88.5%) were
on a combination of a thiazide or thiazide-like diuretic and
another drug. In 60.4% of cases the second drug was a
centrally acting antihypertensive, in 19.5% a b-blocker, in
5.4% a calcium antagonist and in 3.2% an ACE inhibitor.
The remaining patients (11.5%) were on other drug
combinations.
There was no significant change in the proportion of
prescriptions for the five most commonly prescribed classes
of antihypertensive drug between the first and last
prescription (Table 11). Significant changes were confined to
the most infrequently prescribed drugs.
Fig. 1. Changes in drug costs by visit at Or Abdurahman CHC.
The graph shows that mean drug costs per prescription
steadily decreased due to a dramatic reduction in the
proportion of costs attributable to 'new consultant' drugs
and a smaller decrease for 'CHC' drugs. There was no
change in the mean cost per prescription of 'consultant'
drugs.
• Significant difference in proportions of drugs prescribed between first and last
prescriptions (c2 test; P < 0.01).
t Dyazide. a similar combination of hydrochlorothiazide and a potassium-sparing
diuretic, was also commonly prescribed. However, it was more expensive than
moduretic and was not included in the GSH guidelines, so has been excluded from
this total.
t This total does not include reserpine where it was prescribed as the combination
product 'rautrax' (reserpine + rauwolfia + KCI). as this is more expersive and is not
included in the GSH guidelines.
Excludes 82 patients receiving no hypertensive drugs at their first or last prescription.
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Blood pressure control
The mean systolic pressure at the first measurement was
slightly lower (155.0 mmHg) than at the last measurement
(156.2 mmHg). The pattern was reversed for diastolic
pressure (88.8 v. 87.9 mmHg). None of these differences
was statistically significant. There were also no significant
differences between the proportion of patients controlled
and uncontrolled at the first and last measurements.
Discussion
The study was based on a large sample of hypertensive
patients followed prospectively. It provides more complete
information on prescribing behaviour than has previously
been reported in South Africa.
The most commonly prescribed drug classes at Or
Abdurahman CHC were similar to those found in previous
studies. 17•T• The overall pattern of prescribing at this CHC
accords well with recommendations for cost-effective
prescribing, with over 85% of prescriptions being for
thiazide or thiazide-like diuretics, centrally acting drugs and
b-blockers.
There was a steady reduction in the mean cost per
prescription for antihypertensive drugs during the study
period and a statistically significant difference of R1.99 in
the mean cost per patient of antihypertensive drugs at the
first and last prescription. This was achieved without any
apparent deterioration in BP control. The mean cost-savings
per patient, demonstrated between the first and last
prescription, would result in a saving of about R23.88 per
patient per year if maintained over 12 months. If applied to
all the hypertensive patients at Or Abdurahman, this would
save this CHC R75 150 per annum on drug costs for
hypertensive treatment.
Further analysis suggested that the decrease was
attributable mainly to the prescribing of cheaper drugs
within drug classes, rather than switching between classes
or a reduction in the number of drugs prescribed. The most
marked changes occurred in costs attributable to drugs that
were withdrawn from routine use during the study ('new
consultant' drugs) and drugs that were wholly under the
control of CHC doctors ('CHC' drugs). There was no
decrease in costs attributable to existing consultant-only
drugs.
Some of the weaknesses of the study have been
commented on in more detail in the accompanying paper."
Lack of monitoring of the method of BP measurement has
been acknowledged. However, we believe that the
conclusion that the overall level of BP control was constant
is justifiable, since there was no change in the method of
measurement during the year and no reason to believe that
there was selective bias operating between the first and last
measurements. Follow-up was limited to a year, so the
possibility of a delayed deterioration of BP control
consequent on the changes in drug treatment cannot be
eXcluded, though we think it is unlikely.
The study clearly has some limitations as an investigation
of the cost-effectiveness of introducing treatment guidelines
and restrictions on the availability of more expensive drugs.
For example, data collection was limited to drug costs and
level of BP control, and no data were collected on side-
effect profiles, quality of life or costs of investigations
associated with drug treatments. However, to investigate
this properly requires randomised controlled trials, and was
beyond the capabilities of our study design. There is also
conflicting published evidence from randomised controlled
trials about the side-effect profile and effect on quality of life
of different antihypertensive drug classes, and the choice of
drug treatment is therefore the subject of much debate.".20
Furthermore, during the study, changes in drug therapy were
only maintained if clinically justified and side-effects
following changes in drug treatment were actively sought by
doctors at the CHC. Any occurrence of side-effects, even if
unnoticed by the patient or limited to the patient's dislike of
the new medication (with no symptoms or signs of known
side-effects), was sufficient grounds to change medication.
We therefore believe it is justifiable to evaluate these
interventions in terms of their effect on drug costs and BP
control.
It is not possible to infer causality from an uncontrolled
study. However, the size of the cost-savings and the pattern
of the changes in prescribing are highly suggestive of an
effect of the guidelines and changed availability of drugs.
The interventions were probably complementary and it is
difficult to ascertain from the data which intervention had the
greatest impact. However, the reduction in aggregated costs
and mean costs per drug prescribed for the 'CHC' drugs
must represent changes in prescribing behaviour
independent of drug availability (since this was unchanged
for these drugs).
The savings demonstrated in this study may be an
underestimate for two reasons. Firstly patients who had had
hypertensive treatment withdrawn were excluded from the
analysis. Their number increased steadily through the year,
so their inclusion would increase estimated cost-savings.
However, in the absence of a control group, it is unclear to
what extent withdrawal of treatment resulted from
implementation of the GSH guidelines.
Secondly, the GSH guidelines were introduced in the
middle of 1991, before monitoring of prescribing and drug
costs began - although they were not fully implemented
until January 1992 (0 W R Lunt - personal observation).
Any resulting reduction in prescribing costs in 1991 would
not have been recorded in our study, and would have
decreased the apparent effect of the guidelines measured
during the study period.
In conclusion, this study suggests that significant savings
in antihypertensive drug costs could be achieved in primary
care in South Africa through the introduction of treatment
guidelines and restriction of the availability of the most
expensive drug treatments, while free access to a range of
cheaper, but still effective, antihypertensive drugs was
maintained. This evidence is especially welcome given the
current debate about the effectiveness of guidelines and the
difficulties of implementation.21.2'
Further work is needed to evaluate the effectiveness of
similar interventions for hypertension and for other common
chronic conditions in other primary and secondary care
settings in the public and private sectors.
The success of these interventions - the clinical
guidelines were introduced voluntarily by the CHC doctors
- illustrates the potential for family physicians to act as
resource managers, one of the principles of family practice!3
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Whether this sort of activity will become widespread in
South Africa is questionable, given the lack of incentives.
The CHC and the community it serves received no financial
benefit from the more economical prescribing during this
study. Perhaps one way to encourage more cost-effective
prescribing is to learn from the UK experience with
fundholding GPs" and to allow all or a proportion of savings
from drug costs to be used to fund improvements in
services and facilities of the institution making the savings.
We would like to thank all the doctors at the day hospital,
especially Dr K Ahmad and Dr R Evans for their participation in
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particularly the nursing and pharmacy staff. We would also like
to thank the Cardiology Unit of the Department of Medicine,
University of Stellenbosch, for funding the data analysis and the
writing up for publication.
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Survival of children in Cape
Town known to be vertically
infected with HIV-1
G D Hussey, R M Reijnhart, A M Sebens,
J Burgess, S Schaaf, S Potgieter
Objective. To determine the survival patterns of children in
Cape Town known to be vertically infected with HIV.
Design. Retrospective record review of children
diagnosed with symptomatic HIV infection during the
period 1 December 1990 - 31 May 1995.
Setting. Hospitals in the Cape Town metropolitan area.
Patients. 193 children were known to be vertically HIV-
infected. HIV diagnosis was based on the following
criteria: two positive HIV enzyme-linked immunosorbent
assays (ELlSAs) in children older than 15 months and a
positive ELlSA together with a positive polymerase chain
reaction (PCR) in younger children. The mothers of the
children were known to be HIV-positive. On the basis of
the presenting clinical findings children were assigned to a
disease severity category (A, B or C) according to the
Centers for Disease Control and Prevention (CDC)'s 1994
revised classification system for HIV infection in children.
Outcome measures. Survival was analysed according to
the Kaplan-Meier method. Survival time was defined as
the length of time between clinical diagnosis of HIV and
death or last contact with the health services. Mortality
risk in relation to specific variables at diagnosis such as
age and clinical manifestations was determined by
calculation of odds ratios (ORs) with 95% confidence
intervals (Cls).
Results. The median age at diagnosis was 5 months;
72% of children were aged less than 1 year at diagnosis.
According to the CDC clinical classification, 47 (24%) fell
into category A, 111 (58%) into category Band 35 (18%)
into category C. Of the 193 patients 85 (44%) were alive at
the time of review, 65 (34%) had died and 43 (22%) were
lost to follow-up. Risk of death was significantly
associated with age less than 6 months (OR 4.7,
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